November 24, 2016 - By Adrian Mccoy
Edwards Lifesciences Corp Chairman & CEO Michael Mussallem on the 23-11-2016 unloaded a total of 49,100 shares of the stock exchange listed company with value $4,157,459 US Dollars. This is calculated with average price per share of $84.7 US Dollars. Michael is trying to decrease his company’s share, same as he did in the last 30 days. He unloaded another 49,100 shares worth $4,555,134 USD. And, It’s sure Michael’s transaction isn’t going to remain undiscovered as he presently is having ownership of 830,864 shares – ( 0.38% of Edwards Lifesciences Corp’s Market Cap ).
Out of 25 analysts covering Edwards Lifesciences Corp (NYSE:EW), 19 rate it a “Buy”, 1 “Sell”, while 5 “Hold”. This means 76% are positive. $195 is the highest target while $86 is the lowest. The $111.71 average target is 29.46% above today’s ($86.29) stock price. Edwards Lifesciences Corp has been the topic of 52 analyst reports since July 30, 2015 according to StockzIntelligence Inc. The firm earned “Neutral” rating on Friday, January 8 by Suntrust Robinson. The rating was maintained by RBC Capital Markets with “Outperform” on Wednesday, February 3. The firm earned “Buy” rating on Monday, April 4 by Jefferies. Citigroup maintained Edwards Lifesciences Corp (NYSE:EW) on Wednesday, July 27 with “Sell” rating. The firm has “Sell” rating given on Thursday, November 12 by Citigroup. The company was maintained on Wednesday, February 3 by Canaccord Genuity. The stock of Edwards Lifesciences Corp (NYSE:EW) earned “Outperform” rating by Credit Suisse on Monday, August 10. The company was maintained on Monday, April 11 by JP Morgan. Stifel Nicolaus maintained the stock with “Buy” rating in Wednesday, October 26 report. The firm has “Buy” rating by Canaccord Genuity given on Monday, May 23.
About 2.21 million shares traded hands. Edwards Lifesciences Corp (NYSE:EW) has declined 21.33% since April 21, 2016 and is downtrending. It has underperformed by 26.66% the S&P500.
Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The company has a market cap of $17.71 billion. The Firm makes heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. It has a 34.35 P/E ratio. It develops hemodynamic monitoring systems used to measure a patient’s cardiovascular function in the hospital setting.
According to Zacks Investment Research, “Edwards Lifesciences Corporation provides products and technologies to treat late-stage cardiovascular disease. The Company’s products include tissue replacement heart valves, heart valve repair products, hemodynamic monitoring devices, angioscopy equipment, oxygenators, and pharmaceuticals. Edwards Lifesciences Corporation is headquartered in Irvine, California.”
Analysts await Edwards Lifesciences Corp (NYSE:EW) to report earnings on February, 7. They expect $0.73 EPS, up 15.87% or $0.10 from last year’s $0.63 per share. EW’s profit will be $149.82M for 29.55 P/E if the $0.73 EPS becomes a reality. After $0.68 actual EPS reported by Edwards Lifesciences Corp for the previous quarter, Wall Street now forecasts 7.35% EPS growth.
More news for Edwards Lifesciences Corp (NYSE:EW) were recently published by: Wsj.com, which released: “Edwards Lifesciences Shares Fall After-Hours” on October 25, 2016. Forbes.com‘s article titled: “RSI Alert: Edwards Lifesciences (EW) Now Oversold” and published on November 22, 2016 is yet another important article.
Edwards Lifesciences Corporation, incorporated on September 10, 1999, is focused on technologies that treat structural heart disease and critically ill patients. The Firm makes heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. It develops hemodynamic monitoring systems used to measure a patient’s cardiovascular function in the hospital setting. The Firm conducts activities around the world and is managed in various geographical regions, including the United States, Europe, Japan, and Rest of World. All regions sell products that are used to treat advanced cardiovascular disease. The Company’s products and technologies it offers to treat advanced cardiovascular disease are categorized into three areas: Transcatheter Heart Valve Therapy, Surgical Heart Valve Therapy and Critical Care.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Adrian Mccoy